Mirago S 50 Combikit is a fixed-dose combination medication containing mirabegron (50mg) and solifenacin (5mg) in a single tablet formulation. This product is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary frequency, urgency, and incontinence. Mirabegron, a beta-3 adrenergic receptor agonist, works by increasing the bladder's capacity to store urine, reducing the frequency of urination and urgency. Solifenacin, a muscarinic receptor antagonist, inhibits the muscarinic receptors in the bladder, reducing involuntary muscle contractions and the urge to urinate. The combination of these two agents in Mirago S 50 Combikit provides a synergistic effect in managing OAB symptoms. The medication is available in a once-daily tablet and should be taken with water. The recommended starting dose is one tablet, and the dose may be adjusted based on individual patient response and tolerability. As with any medication, Mirago S 50 Combikit may cause side effects, including dry mouth, constipation, and urinary retention, and should be used under the guidance of a healthcare provider.